Key indicators: single-crystal X-ray study; T = 296 K; mean (C-C) = 0.005 Å; R factor = 0.057; wR factor = 0.175; data-to-parameter ratio = 13.2.
The asymmetric unit of the title compound, C 17 H 20 ClN 2 + Á-C 6 H 2 N 3 O 7 À ÁH 2 O, contains a piperazin-1-ium cation, a picrate anion and one solvent water molecule. The piperazene ring is protonated at one N atom and adopts a highly distorted chair conformation with the chloropheny(phenyl)methyl substituent on the second N atom in an equatorial position. The crystal structure is stabilized by O-HÁ Á ÁO, N-HÁ Á ÁO and C-HÁ Á ÁO hydrogen bonds.
Related literature
For the biological activity of 1-benzylpiperazine, see: Campbell et al. (1973) . For related structures, see: Jasinski et al. (2011); Song et al. (2012) . For bond-length data, see: Allen et al. (1987) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). (Campbell et al., 1973) and its derivatives were found to possess excellent pharmacological activities. These include vasodilator, hypotensive and antiviral activity, the ability to increase cerebral blood flow and broad pharmacological action on central nervous system. In the course of our studies on the salts of piperazines (Jasinski et al., 2011; Song et al., 2012) and in view of the importance of piperazines, the paper reports the crystal and molecular structure of the title piperazin-1-ium salt.
The molecular structure and atom numbering scheme of the title compound are shown in Fig 1. In the title compound, the piperazine group is protonated at the N2 atom and adopts a highly distorted chair conformation with puckering A view of the title compound with the atom numbering scheme. Displacement ellipsoids for non-H atoms are drawn at the 50% probability level.
4-[(4-Chlorophenyl)(phenyl)methyl]piperazin-1-ium 2,4,6-trinitrophenolate monohydrate
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